SPACR Activators
SPACR Activators are a distinct group of compounds that specifically enhance the activity of SPACR by modulating various cellular signaling mechanisms. Forskolin, acting directly on adenylate cyclase, elevates cAMP levels, which in turn activates PKA; this activated PKA is then capable of phosphorylating SPACR, leading to an enhancement of SPACR's activity in cell signaling. IBMX supports this cAMP-mediated enhancement by inhibiting phosphodiesterases, thereby preventing the degradation of cAMP and ensuring prolonged PKA activation and subsequent phosphorylation of SPACR. PMA, by activating PKC, may influence SPACR through phosphorylation, thus reinforcing its role within specific signaling pathways. Meanwhile, Sildenafil and Zaprinast elevate cGMP levels by inhibiting phosphodiesterase type 5, with the elevated cGMP activating PKG which may phosphorylate and enhance SPACR activity.
Additionally, Chlorophenylthio-cAMP and Rolipram contribute to this activation network; the former provides a stable cAMP analog that resists degradation, while the latter selectively inhibits phosphodiesterase 4, both culminating in increased PKA activity and subsequent enhancement of SPACR function. Vinpocetine and Milrinone, as phosphodiesterase inhibitors, raise both cAMP and cGMP levels, thus activating PKA and PKG which may target SPACR to boost its signaling activities. Anagrelide and EHNA, by inhibiting phosphodiesterase 3 and adenosine deaminase respectively, also lead to increased levels of cAMP, thereby activating PKA which is known to phosphorylate SPACR enhancing its activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylate cyclase, increasing intracellular cAMP levels. Elevated cAMP activates PKA, which can phosphorylate SPACR, resulting in enhanced functional activity related to its role in cell signaling. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a nonspecific inhibitor of phosphodiesterases, which prevents cAMP degradation, thereby sustaining PKA activation. PKA activity leads to phosphorylation events that enhance SPACR function in signal transduction. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a potent activator of protein kinase C (PKC). Activated PKC may phosphorylate SPACR, thus enhancing its activity within cellular signaling pathways where SPACR is a downstream effector. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective inhibitor of phosphodiesterase 4, leading to an increase in cAMP levels which activates PKA. Activated PKA may enhance the functional activity of SPACR by phosphorylation. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast inhibits phosphodiesterases 5, 6, and 9, increasing cGMP levels. Elevated cGMP can activate PKG, which may phosphorylate SPACR, leading to an increase in its cellular activity. | ||||||
Vinpocetine | 42971-09-5 | sc-201204 sc-201204A sc-201204B | 20 mg 100 mg 15 g | $55.00 $214.00 $2400.00 | 4 | |
Vinpocetine is a phosphodiesterase 1 inhibitor, which elevates cAMP and cGMP levels, potentially leading to activation of PKA and PKG. These kinases may target SPACR, enhancing its cellular activity. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $92.00 $357.00 | 16 | |
Cilostamide is a selective inhibitor of phosphodiesterase 3, which increases cAMP levels, thereby activating PKA. PKA can then phosphorylate SPACR, potentially enhancing its activity in cellular signaling. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $165.00 $697.00 | 7 | |
Milrinone selectively inhibits phosphodiesterase 3, leading to increased cAMP levels and subsequent PKA activation. PKA can phosphorylate SPACR, which could result in the enhancement of its signaling functions. | ||||||
Anagrelide hydrochloride | 58579-51-4 | sc-203513 sc-203513A | 10 mg 50 mg | $103.00 $587.00 | 1 | |
Anagrelide inhibits phosphodiesterase 3, leading to increased cAMP levels, which in turn activates PKA. Enhanced PKA activity can lead to the phosphorylation and activation of SPACR within its signaling pathways. | ||||||